PEOPLE - BioTransplant (US) makes appointment:
This article was originally published in Clinica
BioTransplant (Charlestown, Massachusetts), a developer of therapeutic devices and treatments for a range of medical conditions, has appointed Donald Hawthorne, Anthony Hitschler and Gregg Summerville to the board. Mr Hawthorne currently serves as BioTranspolant's president and CEO, Mr Hitschler serves as president of Brandywine Asset Management and Mr Summerville serves as chief investment strategist at Kirr, Marbach & Company.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.